spacer
home > ict > autumn 2016 > does size really matter?
PUBLICATIONS
International Clinical Trials

Does Size Really Matter?

Over the past few years, outsourcing clinical trials has become an attractive option for sponsored pharmaceutical research. Therapeutic expertise, resource management, technological advantages and cost cutting are some of the primary reasons for any biopharmaceutical sponsor to outsource clinical trials. This has led to tremendous growth in the size and number of CROs in the past two decades. Most of them position themselves as a fullservice CRO in the drug development market, although – based on study-specific requirements – the majority of them are ready to sub-source for their functional needs.

Collaborating with a CRO is now an essential and significant step for sponsors during the clinical development process. The dynamic shift in outsourcing methodology and service fragmentation has left them with critical decisions to be taken at the juncture of CRO sourcing. There are variable sizes of companies on both the sponsor and the CRO side, and the principle of ‘one size fits all’ is not pragmatic from an operability perspective.

Different Options


Full-service and functional outsourcing remain as two distinct but basic models of collaboration. Traditionally, per-study outsourcing has been followed until recently, when strategic partnerships between Big Pharma and sizeable CROs began gaining popularity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Mohamed El Malt, MD, PhD, is Chief Medical Consultant at Europital. In addition to 15 years of working as a general and oncology surgeon, Mohamed has more than 32 years of experience as a medical doctor, 18 of which he spent in clinical research and drug development at academic medical centres, as well as in pharma companies and CROs as an investigator, project leader and medical director.
spacer
Mohamed El Malt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us. Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan:
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement